With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Subscribe To Our Newsletter & Stay Updated
